Literature DB >> 8101967

Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.

P G Strange1.   

Abstract

At least five receptors for dopamine (D1-D5) have been recognised from molecular biological studies, and their pharmacological properties and brain localisations have been determined. The D1 and D2 subtypes are the principal subtypes in brain, and their cellular localisations in the caudate nucleus and putamen have been determined. With recent advances in the understanding of basal ganglia neuronal function, these localisation data enable insights into the mode of action of drugs used at present and in the future to treat Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101967     DOI: 10.1002/mds.870080303

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

1.  Dopamine receptor modulation of repetitive grooming actions in the rat: potential relevance for Tourette syndrome.

Authors:  Jennifer L Taylor; Abha K Rajbhandari; Kent C Berridge; J Wayne Aldridge
Journal:  Brain Res       Date:  2010-01-28       Impact factor: 3.252

2.  Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans.

Authors:  Jo Ann V Antenor-Dorsey; Joanne Markham; Stephen M Moerlein; Tom O Videen; Joel S Perlmutter
Journal:  Nucl Med Biol       Date:  2008-04       Impact factor: 2.408

Review 3.  Mutational and biochemical analysis of dopamine in dystonia: evidence for decreased dopamine D2 receptor inhibition.

Authors:  R D Todd; J S Perlmutter
Journal:  Mol Neurobiol       Date:  1998-04       Impact factor: 5.590

Review 4.  Parkinson's disease.

Authors:  J R Playfer
Journal:  Postgrad Med J       Date:  1997-05       Impact factor: 2.401

Review 5.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 6.  Glutamate and Parkinson's disease.

Authors:  F Blandini; R H Porter; J T Greenamyre
Journal:  Mol Neurobiol       Date:  1996-02       Impact factor: 5.590

7.  Effects of the DRD4 genotype on neural networks associated with executive functions in children and adolescents.

Authors:  Susanne Gilsbach; Susanne Neufang; Susann Scherag; Timo D Vloet; Gereon R Fink; Beate Herpertz-Dahlmann; Kerstin Konrad
Journal:  Dev Cogn Neurosci       Date:  2012-05-31       Impact factor: 6.464

Review 8.  Clinical pharmacology of dopamine agonists in Parkinson's disease.

Authors:  K W Lange
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 4.271

9.  Dopamine in plasma - a biomarker for myofascial TMD pain?

Authors:  Andreas Dawson; Niclas Stensson; Bijar Ghafouri; Björn Gerdle; Thomas List; Peter Svensson; Malin Ernberg
Journal:  J Headache Pain       Date:  2016-07-07       Impact factor: 7.277

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.